Skip to main content
EJNMMI Research

Table 1 Baseline patient characteristics (N = 153)

From: [18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy

Age, (y)

49

(39–55)

Diagnostic imaging

 Tumor size MRI (mm)

30

(22–47)

 FDG-positive ALNs

2

(1–4)*

Clinical tumor stage

 cT ≤ 1

33

(22%)

 cT2

86

(56%)

 cT ≥ 3

33

(22%)

Clinical axillary stage

 cALN<4

108

(71%)

 cALN≥4

45

(29%)

Histology

 Ductal

136

(89%)

 Lobular

15

(10%)

 Other

2

(1%)

Tumor subtype

 HR+/HER2−

71

(46%)

 HR+/HER2+

24

(16%)

 HR−/HER2+

18

(12%)

 Triple-negative

40

(26%)

Grade

 Grade 1

3

(2%)

 Grade 2

77

(53%)

 Grade 3

65

(45%)

 Unknown

7

–

  1. Data are median (IQR) or N (%)
  2. *The number of FDG-avid nodes was reported as ≥ 10 in 15 patients, in which case the cut-off value of 10 was used
  3. cALN<4 less than four FDG-positive axillary lymph nodes, cALN≥4 more than four FDG-positive axillary lymph nodes, MARI marking axillary lymph nodes with radioactive iodine seeds, ALNs axillary lymph nodes
Back to article page